Japan Lifeline Co., Ltd. will acquire all shares of Cross Vascular, Inc. through JLL Med USA and make an additional capital injection into the company. Number of shares acquired: 8,900,000 shares; purchase price: approx. 977 million yen; JLL Med USA will be 100% owned. The subsequent impact is expected to be minimal, and local establishment is scheduled for August 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7575","jir_company_name":"Japan Lifeline Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/7575-20260929-01.pdf","jir_short_summary":"Japan Lifeline Co., Ltd. will acquire all shares of Cross Vascular, Inc. through JLL Med USA and make an additional capital injection into the company. Number of shares acquired: 8,900,000 shares; purchase price: approx. 977 million yen; JLL Med USA will be 100% owned. The subsequent impact is expected to be minimal, and local establishment is scheduled for August 2026.","jir_summary":"### Overview of the Acquisition\nJapan Lifeline Co., Ltd. will acquire all shares of U.S.-based Cross Vascular, Inc. through JLL Med USA Inc., making the company a 100% subsidiary. The acquisition price is estimated at approx. 977 million yen and includes an earn-out structure. Cross Vascular provides a high-frequency system for transseptal puncture and has products that have obtained FDA 510(k) clearance.\n\n### Future Developments and Impact\nJLL Med USA is slated to be established in August 2026 and will lead sales promotion in the U.S. market. Through the acquisition and capital injection, the company aims to expand its global portfolio and strengthen its business foundation in the U.S. The direct impact on future performance is expected to be minimal and will be disclosed as appropriate.","jir_financial_highlights":"Number of shares acquired: 8,900,000 shares (Unknown)\nAcquisition price: approx. 977 million yen (Breakdown: payment to shareholders 734 thousand USD, earn-out up to 4,000 thousand USD, advisory fees, etc. approx. 234 million yen)\nCapital injection amount: 7,265 thousand USD (Unknown)","jir_category":"","jir_hashtags":"#CrossVascularAcquisition, #USMarketExpansion","jir_key_figures":"Number of shares acquired: 8,900,000 shares\nAcquisition price: approx. 977 million yen\nCapital injection amount: 7,265 thousand USD","jir_meta_title":"Japan Lifeline Co., Ltd. Announces Acquisition of Cross Vascular and Capital Injection\uff5cSeptember 2026","jir_meta_description":"Japan Lifeline Co., Ltd. will make Cross Vascular, Inc. a wholly owned subsidiary and execute a capital injection. Summary of key points including number of shares acquired, acquisition price, and capital injection amount. Impact is expected to be minimal; local establishment scheduled for August 2026. See IR materials for details.","jir_og_title":"Announcement of Cross Vascular Acquisition\uff5cJapan Lifeline Co., Ltd. M&A","jir_og_description":"Japan Lifeline Co., Ltd. acquires and injects capital into U.S. Cross Vascular: 8,900,000 shares acquired, approx. 977 million yen, capital injection 7,265 thousand USD. Watch for future business developments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9484,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-124468","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n